Labcorp’s Post

Delve into the debate over new Alzheimer’s criteria and the implications for early diagnosis and treatment. Learn about the latest updates and controversies shaping Alzheimer's research and clinical practice. #Alzheimers #HealthcareDebate #MedicalEthics #Alzheimersresearch #earlydiagnosis #medicalcontroversies #clinicalpractice #brainhealth #dementiaawareness

We're entering a new era of Alzheimer's drugs and therapies, offering new hope for patients and families. Truveta is empowering the next generation of Alzheimer's research, with more than 600K Alzheimer's patient journeys, 247M labs, and 51M medication orders. Learn more: https://tr.vet/3qDynmj #AlzheimersDisease #Alzheimers #AlzheimersDrugs #AlzheimersResearch #MedicalResearch #Donanemab #HealthTech #HealthResearch #HealthData #PatientJourneys #PatientCare #Leqembi

Participate in an Alzheimer's Clinical trial and make an impact in the Alzheimer’s community. Learn more: https://lnkd.in/eRnzWi3f #alzheimers #alzheimersawareness #alzheimerscare #ClinicalTrials #PatienTrials

Shining a Light on Alzheimer's: The Benefits of Light Therapy! Did you know that light therapy could be a game-changer for Alzheimer's patients? Recent studies have shown that exposure to certain light wavelengths can have a profound impact on their overall well-being and quality of life. If you want to dive deeper into this fascinating topic, check out this article: 🔗 Link: https://hubs.ly/Q02kwz4f0 #LightTherapy #AlzheimersAwareness #ShiningALightOfHope #QualityOfLife #InnovationInHealthcare #improvelifewithlight

We are thrilled to celebrate the remarkable achievements of our Chief Scientific Officer, Dr. Andreas Jeromin, as highlighted in his recent interview with G2 Intelligence. Dr. Jeromin discussed the ongoing vital progress towards achieving regulatory approval for blood tests to aid in #Alzheimer's diagnosis. Use of blood tests including #ALZpathDx represent a pivotal advancement in the detection and care of Alzheimer’s, offering a non-invasive and more accessible method for early Alzheimer's diagnosis. We are optimistic about the profound impact these innovations will have on the lives of the 55 million diagnosed with Alzheimer’s disease today and the millions yet to be diagnosed. #AlzheimersResearch #ALZpath #HealthInnovation #pTau217

Blood tests are non invasive methods that could make a huge difference in being able to more definitely diagnose #dementia. Given that up to 50% of people go undiagnosed, having access to a validated method would be a significant step forward. But there is a lot of nuance to consider here, what is the diagnostic criteria and cut off levels? Would it be used to screen and if so what happens to false positives? What about overall access given the current gaps in the health system? The optimist in me hopes that it will enable better pathways of care, more funding and push for quality of care and therapeutics if more people are diagnosed. But it’s not hard to see how poorly thought through policy can have huge impacts.